Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Primary Myelofibrosis 3Myeloproliferative Disorders 3Pancreatic Neoplasms 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Thrombocytosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Melanoma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Prolymphocytic, T-Cell 1Leukemia, Myeloid, Acute 1Inhibition, Psychological 1Hodgkin Disease 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1B-cell Malignancies 1B-Cell Malignancies 1

Interventions

fludarabine phosphate 6Whole-Body Irradiation 5Mycophenolic Acid 5Peripheral Blood Stem Cell Transplantation 4Cyclosporins 4Cyclosporine 4Cyclophosphamide 3Alemtuzumab 3fludarabine 2carmustine, poliferprosan 20 drug combination 2Stem Cell Transplantation 2Sirolimus 2Melphalan 2Etoposide 2Cytarabine 2Carmustine 2venetoclax 1thymoglobulin 1romidepsin 1niraparib 1nelarabine 1letermovir 1itacitinib 1ibrutinib 1Tacrolimus 1Mitoxantrone 1Interleukin-15 1INCB039110 1Hematopoietic Stem Cell Transplantation 1GRN163L peptide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Leukemia, Prolymphocytic, T-Cell × itacitinib × Clear all
NCT03989466 2024-10-10

Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia

M.D. Anderson Cancer Center

Phase 1 Completed
15 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Prolymphocytic, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡